Ongoing Pharma-Initiated Clinical Trials
2021
Safety, tolerability and effectiveness of ofatumumab in patients with relapsing MS (ALITHIOS study)
2021
Ocrelizumab treatment of relapsing MS (CASTING/LIBERTO study)
2021
Ocrelizumab treatment of progressive MS (CONSONANCE study)
2021
Dimethyl fumarate observational study (ESTEEM study)
2021
Cognition and health-related quality of life in patients with highly active relapsing MS (CLARIFY MS Extension study)
2021
Effectiveness and safety of ocrelizumab in patients with early stage relapsing MS (ENSEMBLE/LIBERTO study)
2021
Efficacy and safety of fenebrutinib in patients with primary progressive MS (FENtrepid study)
Completed Pharma-Initiated Clinical Trials
The year refers to the date of publication (PubMed) or latest update on ClinicalTrial.gov
2021
Quality of life in patients with highly active relapsing MS (CLARIFY MS study)
2021
Plegridy observational program (POP study)
2020
The efficacy and safety of ponesimod (POINT study)
2020
Ofatumumab versus teriflunomide in relapsing MS (ASCLEPIOS I study)
2020
Efficacy and safety of dimethyl fumarate in pediatric patients with relapsning MS (CONNECT study)
2020
Safety of fingolimode in patients with MS
2019
Long-term extension study to evaluate safety and efficacy of daclizumab (EXTEND study)
2019
Vitamin D3 as an add on to IFN-beta 1-alpha in treatment of relapsing MS (SOLAR study)
2018
Natalizumab treatment of secondary progressive MS (ASCEND study)
2018
Subcutaneous IFN-beta 1-alpha treatment of relapsing MS (ScanSmart study)
2018
Subcutaneous ofatumumab treatment of relapsing MS (MIRROR study)
2017
Long-term follow up of fingolimod in relapsing MS (ACROSS study)
2017
Optical coherence tomography in relapsing MS (OCTIMS study)
2017
Ocrelizumab treatment of primary progressive MS (ORATORIO study)
2016
Oral fingolimod in primary progressive MS (INFORMS study)
2016
Natalizumab re-initiation of dosing (STRATA study)
2015
Observational study of subcutaneous IFN-beta 1-alpha treatment of relapsing MS (SMART study)
2015
Daclizumab versus IFN-beta 1-alpha treatment of relapsing MS (DECIDE study)
2014
Efficacy and safety of teriflunomide in patients with relapsing MS (TERACLES study)
2014
Observational study of patients with relapsing MS converting to glatiramer acetate (COPTIMIZE study)
2014
Efficacy of converting to natalizumab in treatment of active MS (SURPASS study)
2013
Safety and efficacy of autologous mesenchymal stem cell treatment of active MS (MESEMS study)
2012
Firategrast treatment of relapsing MS
2011
Subcutanous IFN-beta 1-alpha in patients with a first clinical demyelinating event (REFLEX study)
2011
Teriflunomide treatment of relapsing MS (TEMSO study)
2011
Efficacy and safety of MBP8298 treatment of secondary progressive MS (MAESTRO study)
2010
Cladribine treatment of relapsing MS (CLARIFY study)
2009
Effect of glatiramer acetate on conversion to clinically definite MS (PreCISe study)
2009
Fingolimod treatment of relapsing MS
2009
Fatique outcome in copaxone users (FOCUS study)
2007
IVIG in postpartum relapsing MS (GAMPP study)
2007
Combination therapy of natalizumab and IFN-beta 1-alpha in relapsing MS (SENTINEL study)
2007
3-year follow up of the BENEFIT study (BENEFIT extension study)
2006
Natlizumab treatment of relapsing MS (AFFIRM study)
2006
IFN-beta 1-beta treatment of patients with CIS (BENEFIT study)
2006
Glatiramer acetate treatment of relapsing MS (CORAL study)
2006
Early treatment of MS with IFN-beta 1-alpha (ETOMS study)
2005
IV immunoglobulin treatment in acute opticus neuritis
2004
Intravenous immunoglobulin in secondary progressive MS (ESIMS study)
2001
Liver and thyroid function and autoimmunity during IFN-beta 1-beta treatment (BEST study)
2001
IFN-beta 1-alpha treatment of secondary progressive MS (SPECTRIMS study)
2000
Linomide in the treatment of MS